ADPT יחס מהיר Adaptive Biotechnologies

Adaptive Biotechnologies is scaling the implementation of clonoSEQ through multi-million dollar contracts, leveraging its patent-protected immunosequencing platform. The real-time coverage ratio demonstrates current solvency, where the value 4.55 represents the current metric. Business development is based on the creation of diagnostic tests in collaboration with cloud behemoths and leading pharmaceutical corporations.

For Adaptive Biotechnologies (ADPT), which combines stable diagnostic revenue with high-risk pharmaceutical partnerships, this ratio determines the ability to cover obligations without liquidating inventory. By analyzing this solvency metric excluding inventories, an investor can see the ratio of liquid assets and accounts receivable to current liabilities, confirming the company's financial autonomy in the face of market shocks.